Figure 5

(A).Bcl-2 expression in LCL8664 cells treated with IL-6. LCL8664 cells were treated with IL-6 (20 ng/ml), or were untreated (untr), for time intervals between 1 – 24 hours. Bcl-2 expression was examined by intracellular flow cytometry. As a positive control, Bcl-2 expression in Jurkat cells was detected using the same methodology. (B). Immunoblot analysis of Mcl-1 expression in LCL8664 cells treated with IL-6 and/or TGF-β1. In the left panel, LCL8664 cells were treated with IL-6 (20 ng/ml) for time intervals between 0 – 24 hours. In the right panel, LCL8664 cells were treated with IL-6 (20 ng/ml), TGF-β1 (1 ng/ml), both, or were untreated (C) for 4 hours. The expression of β-tubulin was examined as a loading control. (C). Activated (phosphorylated) Akt expression in LCL8664 cells treated with IL-6. LCL8664 cells were treated with IL-6 (20 ng/ml), or were untreated (untr), for time intervals between 0 – 60 minutes. Phosphorylated Akt (p-Akt) expression was examined by intracellular flow cytometry. As a positive control, p-Akt expression in Jurkat cells was detected using the same methodology, in the presence or absence of LY294002 (50 βM).